the aid library

National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults

Federal Ministry of Health Nigeria , World Health Organisation (WHO) (2010) C_WHO

Essential List for screening, monitoring and treatment for diabetic retinopathy

International Agency for Prevention of Blindness IAPB (2018) C1

3rd edition April 2018 - draft version This Essential List for Diabetic Retinopathy contains recommendations for a range of essential itemsrequired at community / primary level (for screening); at secondary and tertiary levels (for treatment and follow up). It also contains recommendations for i ... more

Checklist to ensure the meaningful engagement of young persons with disabilities in humanitarian action

UN Youth Office; United Nations Population Fund (2023) CC

After the earthquake in Türkiye-Syria in February 2023 an emergency response was provided to the affected population. Young persons with disabilities were one of the social groups most affected by the crisis. These were either young persons who acquired a disability due to the earthquake, or young ... more

Global Database of Age-friendly Practices

World Health Organization WHO (2015) C_WHO

As the global population ages, cities around the world are striving to become more “age-friendly”. InWHO’s Global Database of Age-friendly Practices, find out what your city is doing to improve the lives of older people. Browse the database to find out.

Tips on Nutrition Interventions for the Humanitarian Response Plan

Nutrition Cluster (2016) CC

Hospital safety Index Guide for Evaluators. Forms

World Health Organization WHO World Health Organization and Pan American Health Organization (2015) C_WHO

checklist

Research Monograph of the Updated 2010-2016 Philippine Plan of Action to Control Tuberculosis

National TB Control Program, Department of Health (2014) C1

Leap Health- the mhealth Platform

Health Enablement and Learning Platform (HELP) Project (2017) CC

The Global strategy and action plan on ageing and health

World Health Organization WHO (2017) C_WHO

Specifically the Strategy focuses on five strategic objectives: commitment to action on Healthy Ageing in every country; developing age-friendly environments; aligning health systems to the needs of older populations; developing sustainable and equitable systems for providing lon ... more

National hiv testing services communication strategy 2015 - 2019

National AIDS STI Control Programme (NASCOP), Ministry of Health, Government of Kenya (2015) C1

Strategic communication is used to raise awareness of issues among specific target populations. It aims to provide timely, evidence-based, authoritative information and guidance needed for public health action. Proper implementation of strategic communication leads t ... more

Manual de procedimientos para la vigilancia y el control de las leishmaniasis en la Región de las Américas

Pan American Health Organization (PAHO) (2023) C_WHO

La Organización Panamericana de la Salud se complace en presentar la segunda edición del Manual de procedimientos para la vigilancia y el control de las leishmaniasis en la Región de las Américas, un instrumento de apoyo a las áreas de gestión y de servicios que trabajan con la leishmaniasis e ... more

Kenya HIV Prevention Revolution Road Map. Countdown to 2030

Ministry of Health, Kenya (2014) C1

Rehabilitation Surgery for deformities due to poliomyelitis

World Health Organization (1993)

Techniques for the district Hospital

Care of Small and Sick Newborns in Special Newborn Care Units (SNCUs) of India: Two year report April 2013 – March 2015

Ministry of Health & Family Welfare, Government of India (2017) C2

This report provides a comprehensive overview of the progress made by India in terms of establishment and functionality of Special Newborn Care Units (SNCUs) during the two year period from April 2013 to March 2015. It describes the progress in the operational status (numbers, bed strength, human re ... more

The Kenya Urban Reproductive Health Initiative (Tupange) Endline Findings for Mombasa

Kenya National Bureau of Statistics, MLE Initiative (2015) C1

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Education Capacity Self-Assessment: Transforming the Education Humanitarian Response of the Rohingya Refugee Crisis (Cox’s Bazar, Bangladesh, March 2018)

UN Children's Fund, BRAC, Education Cluster, Norwegian Capacity (2018) CC

India: Guidelines for the Public Private Partnership Model of ART centres

National AIDS Control Organisation (NACO), Government of India (2017) C1